Financial Data and Key Metrics Changes - Q4 revenues were $42.3 million, an increase of $4.6 million or 12% from $37.7 million in the same period last year [16] - Full year revenue was $150.5 million, an increase of $8 million or 6% from $142.6 million reported last year [16] - Adjusted EBITDA for Q4 was approximately $460 thousand, compared to $631 thousand for the same period last year [22] - Free cash flow for Q4 was $335 thousand, compared to $593 thousand in the same period last year [23] - Net loss for Q4 was $849 thousand, or a loss of $0.09 per share, compared to a net loss of $356 thousand and a loss of $0.04 per share for the same period last year [24] Business Line Data and Key Metrics Changes - Carrier services revenue for Q4 was $26.8 million, an increase of $2.2 million compared to the same period last year [17] - Managed services fees for Q4 were $10.5 million, an increase of $1.1 million from the same period last year [17] - Reselling and other services in Q4 was $3.9 million, a $1.2 million increase from last year [18] - Gross profit for Q4 was $5.8 million or 14% of revenues, compared to $4.8 million or 13% of revenues in the same period last year [19] Market Data and Key Metrics Changes - Approximately $80 million in contract ceiling remains under the CWMS 2.0 contract [5] - The company expects to see an update from DHS by mid-second quarter regarding CWMS 3.0 award announcement or another extension [5] Company Strategy and Development Direction - The company is focused on CWMS 3.0, which carries a $3 billion contract ceiling over 10 years, offering significant revenue visibility [29] - The company aims to improve its margin profile through SaaS and DaaS pipeline initiatives [30] - The company is transitioning select existing clients towards an as-a-service model to enhance revenue visibility and predictability [9] Management's Comments on Operating Environment and Future Outlook - Management remains confident in WidePoint's competitive positioning despite delays in CWMS 3.0 award due to federal government headwinds [3] - The company is optimistic about landing several opportunities in its pipeline throughout 2026 [10] - Management emphasized the importance of maintaining a strong balance sheet to weather potential government shutdowns [48] Other Important Information - The company has plans to file a prospectus to establish an at-the-market offering program to enhance financial flexibility [27] - The company ended the year with $9.8 million in unrestricted cash and has additional liquidity options available [26] Q&A Session Summary Question: Clarification on DaaS transition and warehouse operations - Management explained the transition from IT as-a-service to DaaS, emphasizing the new warehouse capabilities in Columbus, Ohio, which will allow for better revenue predictability and profitability [33][35] Question: Update on Spiral 4 contract with the Navy - Management confirmed the capture of eight new task orders under the Spiral 4 contract, with a total contract value of approximately $30-$31 million [40] Question: Cash management and potential uses of cash - Management discussed the importance of maintaining a strong cash position to weather government shutdowns and potential acquisition opportunities [43][48]

Financial Data and Key Metrics Changes - SeaStar Medical reported net revenue of over $1 million from QUELIMMUNE sales in 2025, a significant increase from $135,000 in 2024 [21][24] - The fourth quarter of 2025 saw net revenue from QUELIMMUNE sales of approximately $315,000, compared to $67,000 in the fourth quarter of 2024 [19][24] - Gross profit margins for QUELIMMUNE sales were above 90% [4][22] - Operating expenses decreased to $3.4 million in Q4 2025 from $4.8 million in Q4 2024, and for the full year, operating expenses were reduced to $13.4 million from $18 million [23][24] - The net loss for Q4 2025 was approximately $2.9 million, or $0.80 per share, compared to a net loss of $4.4 million, or $8.98 per share in Q4 2024 [23][24] - The company improved its balance sheet by adding approximately $24 million in capital during 2025 and reducing operating liabilities by over $3 million [4][24] Business Line Data and Key Metrics Changes - The QUELIMMUNE therapy expanded its customer base to 16, adding 13 new customers from top-rated children's hospitals [3][4] - The SCD therapy is currently in the NEUTRALIZE-AKI pivotal trial, with 181 of the 339 patients enrolled, achieving over 50% enrollment [4][13] - The company plans to achieve $2 million in product revenue from QUELIMMUNE sales in 2026, a significant increase over 2025 [6] Market Data and Key Metrics Changes - The pediatric AKI market is estimated to be around $100 million, with SeaStar targeting the top 50 children's hospitals in the U.S. [12] - The market opportunity for the adult AKI indication is projected to be 50 times larger than that of the pediatric AKI market [5] Company Strategy and Development Direction - SeaStar Medical aims to advance the SCD therapy for adult AKI and complete enrollment in the NEUTRALIZE-AKI trial by the end of 2026 [5][6] - The company is also exploring broader applicability for the SCD therapy in new indications, including acute congestive heart failure [6][18] - The strategy includes working with the FDA for expedited approval of pipeline indications, leveraging Breakthrough Device Designation [8][18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future potential revenue from the SCD therapy and the ongoing momentum in the pediatric market [5][6] - The management highlighted the importance of QUELIMMUNE in saving lives and its validation in the pediatric AKI field [9][10] - The company is focused on expanding its customer base and enhancing the adoption of QUELIMMUNE therapy [12][51] Other Important Information - SeaStar Medical has no long-term debt and approximately $12 million in cash as of December 31, 2025, compared to $1.8 million at the end of 2024 [24][25] - The company is actively enrolling patients in the NEUTRALIZE-CRS clinical trial for chronic heart failure and cardiorenal syndrome [18] Q&A Session Summary Question: What gives confidence in adding 15 additional pediatric centers for QUELIMMUNE? - Management noted that six sites have already been added in Q1 2026 and emphasized a structured approach to the adoption process [28][30] Question: Is there a need for investment in manufacturing capacity for SCD? - Management expressed confidence in the supply chain and production capacity through their contract manufacturer, Fresenius Medical [31] Question: What are the timelines for the CRS study and next steps if positive? - Management did not provide specific timelines but indicated that a successful study could lead to a humanitarian device exemption for the CRS indication [32][33] Question: How should spending be viewed for this year? - Management indicated that spending would be more in line with 2025 levels, supported by the existing team to execute the plan [34][35]

Financial Data and Key Metrics Changes - Rental income for Q4 2025 was $11 million, down from $11.7 million in the prior year, primarily due to lease expirations [7] - Adjusted funds from operations (AFFO) decreased to $4 million from $4.1 million year-over-year, with AFFO per share dropping from $0.37 to $0.32 [8] - Interest expense increased by $1.1 million compared to Q4 2024, mainly due to amortization of off-market interest rate swaps [10] - Total cash and cash equivalents as of December 31, 2025, were $14.4 million, with $30 million available to draw on the revolver [10] Business Line Data and Key Metrics Changes - The decrease in rental income was attributed to the expiration of leases with Costco and Solar Turbines [7] - The company plans to market the San Diego property for sale upon receiving city approval for a lot split [7] Market Data and Key Metrics Changes - The company noted a challenging environment for asset recycling due to fluctuating interest rates affecting buyer and seller confidence [20] - The current market conditions have led to a tighter pricing environment compared to a year ago, with cap rates tightening [39] Company Strategy and Development Direction - The company aims to recycle non-core assets, particularly in the office sector, and is focused on selling properties that do not fit its long-term strategy [21][24] - The strategy includes a phased approach to asset recycling, with a focus on acquiring high-quality manufacturing properties [31] - The company is committed to maintaining a solid portfolio and is exploring opportunities to extend leases with existing tenants [27] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential for future acquisitions and the ability to clean up the portfolio to enhance value [62] - The leadership believes that the timeline to achieve a 100% pure play manufacturing industrial portfolio remains realistic within 24 months, contingent on market stability [45] - Management acknowledged the current volatility in the macroeconomic environment but sees opportunities for growth and value extraction [40][55] Other Important Information - The company is in the process of selling an office property in Melbourne, Florida, with earnest money of over $400,000 already secured [70] - The operational costs associated with the former Calera property were approximately $20,000-$30,000 per month, which will cease following its sale [74] Q&A Session Summary Question: Reasons for not pursuing a recent acquisition offer - Management indicated that they did not see a secure path forward in the discussions and prioritized protecting investor interests [15][16] Question: Expectations for asset recycling in 2026 - Management stated that asset recycling efforts would pick up, but current market conditions make it challenging for both buyers and sellers [20] Question: Timeline for achieving a pure play manufacturing portfolio - Management affirmed that the 24-month timeline is realistic, depending on market conditions and the availability of suitable assets [45] Question: Factors attracting interest as an acquisition target - Management noted that the persistent discount of public REITs to private real estate has led to increased interest in their portfolio [49][55] Question: Terms of the Melbourne office sale - Management confirmed that the terms are confidential until the deal closes, but earnest money has been secured [70] Question: Operational costs of the former Calera property - Management provided that the operational costs were around $20,000-$30,000 per month, which will no longer be incurred post-sale [74]

Financial Data and Key Metrics Changes - Total revenue in Q4 2025 increased by 0.8% year-over-year to $122.8 million [19] - System-wide comparable restaurant sales in Q4 increased by 6.6%, with company-owned restaurants up 7.3% and franchise restaurants up 3.8% [19] - Restaurant contribution margin in Q4 improved to 14.1%, up from 11.2% in Q4 2024, reflecting a 290 basis point increase [20] - Adjusted EBITDA in Q4 was $7.6 million, an increase of over 88% compared to $4 million in Q4 2024 [22] - Net loss for Q4 was $6.8 million, or a loss of $1.16 per diluted share, compared to a net loss of $9.7 million or a loss of $1.70 per diluted share in the previous year [22] Business Line Data and Key Metrics Changes - Company average unit volumes in Q4 increased by 9.9% to $1.44 million [19] - Average check increased by 5.8% in Q4, which included a 2% effective pricing increase [19] - The company closed 9 company-owned restaurants and 3 franchise restaurants in Q4 [22] Market Data and Key Metrics Changes - System-wide comparable sales growth accelerated to over 9% in Q1 2026 year-to-date [4] - Company comp traffic in Q4 increased by 1.4% [19] - The closures of underperforming restaurants positively impacted comparable sales by approximately 100-150 basis points in Q4 [24] Company Strategy and Development Direction - The company focused on strengthening its core business and restoring consistency across the system in 2025 [10] - Strategic goals for 2026 include developing winning teams, igniting growth, driving guest satisfaction, and delivering strong financial results [9] - The company is exploring strategic alternatives to maximize shareholder value, including refinancing existing debt [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the consistency of performance across the business, citing improved food quality and execution [17] - The company anticipates continued sales momentum and margin improvement in 2026, projecting total revenue of $478 million to $493 million [25] - Management noted that the current macroeconomic environment has made consumers more value-conscious, which the company is addressing through its menu offerings [14] Other Important Information - The company expects to close 30-35 restaurants in 2026 as part of its portfolio optimization project [24] - Capital expenditures for 2026 are estimated to be between $9.5 million and $10.5 million [26] - The company aims to be free cash flow positive and reduce its debt balance by $5 million to $10 million in 2026 [26] Q&A Session Summary Question: What is the contribution of sales transfer to the 2026 guidance? - Management indicated that approximately half of the expected EBITDA improvement in 2026 will be due to closures, with the rest attributed to core business improvements [34] Question: Are there any stimulative benefits from early tax refunds or pressures from external factors? - Management noted no significant impact from tax refunds or external pressures on performance, maintaining consistency in sales growth [36] Question: How does the Delicious Duos mix perform? - The Delicious Duos mix is expected to be around 5%, influenced by strong limited-time offers [38]

Financial Data and Key Metrics Changes - Full year revenue grew approximately 10% to $56.7 million, with fourth quarter revenue at $15.6 million, up 27% year-over-year, indicating significant quarterly acceleration [4][23] - Full year adjusted EBITDA reached $2.9 million, up over 200% from $900,000 in 2024, demonstrating strong operating leverage [5][25] - Fourth quarter adjusted EBITDA was $1.7 million compared to a loss of $0.5 million in Q4 of 2024, marking a $2.2 million swing year-over-year [5][26] Business Line Data and Key Metrics Changes - The company has focused on organic growth, with no major acquisitions in the past year, leading to improved profitability and cash flow [3][4] - The partnership with DealMaker is expected to unlock new revenue opportunities through community capital raises for celebrity and influencer-led brands [9][10] Market Data and Key Metrics Changes - The online capital raising market has been growing rapidly, particularly for celebrity and influencer-affiliated brands, which are among the highest performing categories in community capital raises [11] - The company is targeting consumer products and lifestyle brands primarily at growth and expansion stages, expanding its addressable market beyond traditional PR and marketing [10][12] Company Strategy and Development Direction - The strategic partnership with DealMaker is seen as a significant growth catalyst, allowing the company to leverage its marketing capabilities alongside DealMaker's capital raising platform [9][10] - The launch of Dolphin Intelligence, focused on AI-driven marketing strategies, aims to enhance service offerings and improve operational efficiency [13][15] Management's Comments on Operating Environment and Future Outlook - Management expects continued revenue growth in 2026, driven by organic growth across the agency portfolio and contributions from the DealMaker partnership and Dolphin Intelligence services [17][18] - The company anticipates adjusted EBITDA margin expansion, with a goal of achieving higher margins as revenue grows [18][46] Other Important Information - The company has significant federal and state net operating loss carryforwards of approximately $127 million, which will shield cash payments for taxes as EBITDA grows [6][18] - Expected annualized lease savings of approximately $1 million beginning at the end of 2026 will flow directly to the bottom line due to the company's NOL position [19][20] Q&A Session Summary Question: Can you elaborate on the revenue opportunities from the DealMaker partnership? - The partnership allows the company to scale opportunities in launching consumer products and raising capital for clients, with marketing fees expected to be significant [27][28] Question: What is the expected length of deals and typical investors? - The company anticipates a typical deal length of 6-8 weeks for pre-production and 4 months for the online raise, with investment sizes around $1,000-$2,000 [31][32] Question: When will additional ventures be added to the portfolio? - The company expects to begin vetting promising deals in the second half of April and aims to be in the market with the first venture by summer [34][36] Question: How will Dolphin Intelligence contribute to growth? - The division is expected to provide audits for existing clients and attract new business by offering unique AI-driven marketing capabilities [38][39] Question: What is the timeline for the Youngblood film's streaming rights? - The company anticipates that streaming sales will exceed box office performance, with a better indication of revenue expected by the next earnings call [40][42] Question: Is double-digit organic growth sustainable? - Management believes in the potential for continued organic growth and margin expansion, aiming for higher profitability as operational efficiencies improve [44][46]

Financial Data and Key Metrics Changes - Q4 2025 revenues were $42.3 million, an increase of $4.6 million or 12% from $37.7 million in Q4 2024 [16] - Full year revenue was $150.5 million, an increase of $8 million or 6% from $142.6 million in 2024 [16] - Adjusted EBITDA for Q4 was approximately $460 thousand, compared to $631 thousand in Q4 2024 [23] - Free cash flow for Q4 was $335 thousand, down from $593 thousand in the same period last year [24] - Net loss for Q4 was $849 thousand, or a loss of $0.09 per share, compared to a net loss of $356 thousand and a loss of $0.04 per share in Q4 2024 [25] Business Line Data and Key Metrics Changes - Carrier services revenue for Q4 was $26.8 million, an increase of $2.2 million compared to Q4 2024 [17] - Managed services fees for Q4 were $10.5 million, an increase of $1.1 million from the same period last year [17] - Reselling and other services in Q4 were $3.9 million, a $1.2 million increase from last year [18] - Gross profit for Q4 was $5.8 million or 14% of revenues, compared to $4.8 million or 13% in Q4 2024 [19] Market Data and Key Metrics Changes - Approximately $80 million in contract ceiling remains under the CWMS 2.0 contract [5] - The company expects to see updates from DHS regarding CWMS 3.0 by mid-Q2 2026 [5] Company Strategy and Development Direction - The company is focused on CWMS 3.0, which carries a $3 billion contract ceiling over 10 years, providing significant revenue visibility [29] - The company is transitioning existing clients towards an as-a-service model to enhance revenue visibility and predictability [9] - The company aims to improve its margin profile through SaaS and DaaS pipelines [30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's competitive positioning despite delays in contract awards due to external factors [3] - The company remains optimistic about landing opportunities in its pipeline throughout 2026 [10] - Management highlighted the importance of maintaining a strong cash position to weather potential government shutdowns [48] Other Important Information - The company ended the year with $9.8 million in unrestricted cash and has additional liquidity options available [27] - Plans to file a prospectus for an at-the-market offering program to enhance financial flexibility [28] Q&A Session Questions and Answers Question: Clarification on DaaS transition and warehouse operations - The company is converting existing IT as-a-service customers to a device as-a-service model to improve revenue predictability and profitability [35] Question: Update on Spiral 4 contract with the Navy - The company has captured eight new task orders under the Spiral 4 contract, with a total contract value of approximately $30-$31 million [40] Question: Cash management and potential uses of cash - The company aims to maintain a strong cash position for operational resilience and potential acquisitions, while being cautious with capital expenditures [48]

Financial Data and Key Metrics Changes - Q4 revenue reached $178 million, representing a 35% year-over-year growth, while Gross Booking Value (GBV) was $2.3 billion, up 42% year-over-year [12][14] - Non-GAAP operating margin improved to breakeven, a significant 1,100 basis points increase compared to the previous year, despite a GAAP operating margin of negative 50% due to a one-time charge [13][14] - The company turned free cash flow positive for the first time, a year ahead of schedule [5][14] Business Line Data and Key Metrics Changes - The company signed net new GBV that was over 50% more compared to Q4 of the previous year, indicating strong growth in new customer acquisitions [5][12] - The Reed & Mackay business accounted for roughly 20% of total revenue for FY 2026, but grew at a significantly lower rate than the core Navan platform, which saw growth in the high 40s [30][32] Market Data and Key Metrics Changes - The total addressable market (TAM) for the unmanaged travel market is estimated at $57 billion, with the company targeting this segment through its new Navan Edge platform [9][60] - The corporate travel segment is showing strong growth, with the GBTA index indicating mid- to high-single-digit growth year-over-year, outpacing TSA checks [47] Company Strategy and Development Direction - The company plans to focus on high growth and scaling across all channels and offerings in FY 2027, with continued investment in AI and product innovation [10][14] - The integration of Reed & Mackay into the Navan platform is expected to enhance unit economics and improve sales effectiveness [30][31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining momentum despite geopolitical tensions, noting minimal impact from conflicts in the Middle East [22][46] - The company anticipates revenue growth of 24% for FY 2027, with Q1 guidance suggesting a 30% growth [14][46] Other Important Information - The company has a strong balance sheet with $741 million in cash and short-term investments against $125 million in debt [14] - The company is leveraging AI to enhance customer experience and operational efficiency, with over 70% of expenses automated [20][72] Q&A Session Summary Question: Can you provide insights on the bookings momentum and sustainability? - Management highlighted a 42% GBV growth in Q4 and clarified that the 50% growth mentioned refers to new signed GBV, indicating strong future revenue potential [18] Question: What impact has geopolitical conflict had on bookings? - Management reported minimal impact from geopolitical tensions, with a low volume exposed to the Middle East [22] Question: What benefits are expected from the Reed & Mackay transition? - The integration is expected to enhance customer experience and improve unit economics, with higher gross margins anticipated from the AI-driven Navan platform [30][31] Question: How does the company view its fiscal 2027 guidance? - Management expressed confidence in achieving 24% revenue growth, driven by strong momentum and customer acquisition [46] Question: What is the ramp-up time for new sales representatives? - The ramp-up time varies by segment, with internal promotions typically resulting in faster productivity compared to external hires [91]

Financial Data and Key Metrics Changes - For the year ended December 31, 2025, total revenue was $9.7 million, a significant increase of $5.8 million or 149% compared to $3.8 million in 2024, primarily driven by the launch of Papzimeos [12][16] - Net product revenue for Q4 2025 was $3.4 million, with expectations for Q1 2026 revenues to exceed $18 million based on early commercial activity [4][13] Business Line Data and Key Metrics Changes - The launch of Papzimeos has transitioned the company from an R&D-focused entity to a revenue-generating commercial biotech company, marking a pivotal milestone [3] - The company reported strong momentum in patient uptake, with over 300 patients in the support hub by mid-January, indicating robust demand for Papzimeos [10] Market Data and Key Metrics Changes - Payer coverage for Papzimeos has expanded from approximately 170 million lives in early January to about 215 million, covering nearly 90% of insured lives in the U.S. [10] - The publication of an expert consensus paper has positioned Papzimeos as the first choice for adult patients with RRP, enhancing its market acceptance [11] Company Strategy and Development Direction - The company is actively pursuing geographic expansion, including a marketing authorization application to the EMA for Papzimeos, with positive feedback from European thought leaders [18] - Plans to initiate a clinical trial for Papzimeos in pediatric RRP patients are underway, expected to start in Q4 2026 [18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong uptake of Papzimeos, with expectations for continued revenue growth and institutional activation [11][12] - The company anticipates reaching cash flow breakeven by the end of 2026, supported by projected sales from Papzimeos [17] Other Important Information - Research and development expenses decreased by 22.1% compared to 2024, while selling, general, and administrative expenses increased by 69.8% due to costs associated with Papzimeos commercial activities [14][15] - The net loss attributable to common shareholders for 2025 was $429.6 million, influenced by non-cash items related to preferred stock and warrants [16] Q&A Session Summary Question: Flow of patients from the hub to receiving reimbursed drug - Management indicated that there is significant conversion of patients from the support hub, with a goal to ensure the majority receive treatment [21][24] Question: Patients starting to get their second dose - Management confirmed that patients are progressing through their treatment regimens, with some already receiving their second dose [26][27] Question: Impact of the J-code on patient flow - The J-code is expected to streamline the billing process, enhancing the speed at which patients are processed for treatment [28][34] Question: Clarification on $18 million revenue guidance - The $18 million guidance refers solely to Papzimeos product revenue, excluding other revenue sources [44] Question: Community uptake and prescriber differentiation - Management noted that community sites are showing significant interest in prescribing Papzimeos, aided by logistical support for low-cost access [52][53]

Financial Data and Key Metrics Changes - Operating expenses increased to $7.9 million in 2025 from $4.5 million in 2024, primarily due to the introduction of the biopharma business and increased headcount [12][13] - Cash and cash equivalents rose to $12.6 million at the end of 2025, compared to $2 million at the end of 2024 [14] - Loss from discontinued operations decreased from $1.2 million to $900,000 for the year ended December 31, 2025 [13] Business Line Data and Key Metrics Changes - The company transitioned from a consumer device business to a focused immunotherapy biopharmaceutical company, discontinuing the ClearUP device business and non-core neuromodulation programs [4][12] - The acquisition of Velocity Bioworks is expected to reduce development timelines and costs for Entolimod, while also serving as a revenue driver [9][10] Market Data and Key Metrics Changes - The oncology supportive care market is valued at approximately $15 billion and is expected to grow to $20 billion by the 2030s, with significant unmet needs for next-generation protective agents [6] - Entolimod is positioned to disrupt established markets due to its unique properties that prevent programmed cell death in vital tissues [6] Company Strategy and Development Direction - The company aims to evolve into a high-impact immunotherapy organization, focusing on the TLR5 platform and its lead candidate, Entolimod [3][4] - The strategy includes securing government partnerships and funding for Entolimod, particularly for its use in biodefense against acute radiation syndrome [9][10] Management's Comments on Operating Environment and Future Outlook - Management emphasized that 2025 marked a fundamental transformation for the company, establishing a robust foundation for growth and value creation [17] - The company is committed to executing its vision and looks forward to providing updates as it reaches upcoming milestones [17] Other Important Information - The company is actively engaged with U.S. government agencies to secure funding and support for Entolimod's development [9] - The acquisition of Scorpius Holdings, Inc. for $16.3 million was financed through a senior secured convertible note [14] Q&A Session Summary - No specific questions or answers were provided in the content regarding the Q&A session.

Financial Data and Key Metrics Changes - Total revenue in Q4 2025 increased by 76% sequentially from Q3 2025, indicating early momentum as 5G programs begin contributing to the top line [11] - Net revenues for the full year 2025 decreased by $6.3 million or 69% from $9.1 million in 2024 to $2.9 million in 2025, primarily due to a decrease in product sales and service revenues [12] - Cost of net revenue increased by $0.6 million or 16% from $4.1 million in 2024 to $4.7 million in 2025, largely due to additional production overhead costs [13] - Gross margin for 2025 was negative, reflecting insufficient product revenue to absorb production overhead costs, with expectations for improvement as product volumes increase [13] Business Line Data and Key Metrics Changes - In Q4 2025, the company shipped more than 1,900 5G chipsets for commercial use, marking the early stages of production ramp [4] - Research and development expenses decreased by $3.3 million or 19% from $17.3 million in 2024 to $14 million in 2025, due to the completion of a 5G chip design project [14] - Sales and marketing expenses were relatively flat year-over-year, totaling $4.2 million for 2025 compared to $3.9 million in 2024 [15] Market Data and Key Metrics Changes - The company signed a licensing agreement with a major satellite communications provider, which is expected to create new 5G chipset sales opportunities starting in the second half of 2026 [6] - The partnership with Skylo aims to expand global satellite connectivity for next-generation cellular IoT devices, further demonstrating the flexibility of the company's architecture [8] Company Strategy and Development Direction - The company is focused on transitioning towards full 5G commercialization, expanding its ecosystem of partners and customers, and supporting live network deployments [3][10] - The strategy includes aligning supply chain partners and strengthening production readiness to support the commercialization of the 5G chipset [10] - The company aims to position itself at the intersection of major technology trends, including the expansion of 5G networks and the integration of satellite connectivity with terrestrial infrastructure [9] Management's Comments on Operating Environment and Future Outlook - Management believes the transition from the legacy 4G product cycle to the 5G platform has reached its trough, with expectations for sequential growth in revenue and 5G chipset shipments throughout 2026 [11][17] - The company emphasizes maintaining operational discipline and capital flexibility while supporting the production ramp necessary to convert the growing customer pipeline into meaningful revenue [17] Other Important Information - The company entered into a $20 million convertible note facility during Q4 2025, providing additional resources to support working capital and strategic growth initiatives [9] - As of the end of February 2026, the company had cash and cash equivalents of $9.4 million, along with access to a $75 million equity program [17] Q&A Session Summary Question: Visibility on Fixed Wireless Access and Revenue Trajectory - Management expects to ship more into the Fixed Wireless Access market this year, with growing backlog anticipated as early as Q2 [25] - Revenue from satellite applications is expected to materialize in the second half of the year [25] Question: Revenue Trajectory and Adjusted EBITDA Breakeven - Management indicated that achieving the $25 million revenue target for adjusted EBITDA breakeven could occur in Q1 2027, pending visibility on customer schedules [27] Question: Gross Margins and Operating Expenses - Management does not believe this year's gross margin is representative of future performance, expecting margins to improve to the high 30s%-low 40s% range as product volumes increase [30] - Operating expenses were higher due to one-off situations, including balance sheet cleanup and special charges related to warrants issued to investors [31] Question: Customer Feedback on Product - Customers have expressed satisfaction with the product and the level of support provided, indicating positive feedback and expectations for increased revenue and volume [36] Question: Potential from Satellite Communications Licensing - Management believes the potential from the satellite communications licensing agreement could be significant, with annual quantities expected to be in the million unit range [40][41]